| Description | CU-CPT9b (TLR8-specific antagonist 1) is an antagonist of toll-like receptor 8 (TLR8; Kd = 21 nM). It inhibits activation of NF- B induced by the TLR8 agonist R-848 in TLR8-overexpressing HEK-Blue cells with an IC50 value of 0.7 nM. |
| Target activity | TLR8:0.7 nM (IC50), TLR8:21 nM (Kd) |
| Synonyms | CU-CPT-9b, TLR8-specific antagonist 1 |
| molecular weight | 251.28 |
| Molecular formula | C16H13NO2 |
| CAS | 2162962-69-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (397.96 mM) |
| References | 1. Zhang S , Hu Z , Tanji H , et al. Small-molecule inhibition of TLR8 through stabilization of its resting state[J]. Nature Chemical Biology, 2017, 14(1):58-64. |
| Citations | 1. Yang W, Sun X, Liu S, et al.TLR8 agonist Motolimod-induced inflammatory death for treatment of acute myeloid leukemia.Biomedicine & Pharmacotherapy.2023, 163: 114759. |